Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

Johnson & Johnson has reported data from the Phase III CARTITUDE-4 clinical trial where CARVYKTI (ciltacabtagene autoleucel), ...

Carvykti shows high efficacy in real-world settings, with 89% response and 70% complete response rates among multiple myeloma patients. Despite many patients not meeting clinical trial criteria, ...

Legend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI therapy, featured at the American Society of Hematology meeting, shows promising results in increasing minimal residual ...

Their CARVYKTI therapy, which targets BCMA, has been approved by both the FDA and European Commission, and is expanding its reach globally. This development highlights potential growth ...

After seeing the data, analysts underscored the therapy’s best-in-class potential compared to Johnson & Johnson and Legend Biotech's FDA-approved treatment Carvykti. Abstract data from early and ...

Sales of Johnson & Johnson’s cancer therapy Carvykti and immune disease drug Tremfya grew strongly during the third quarter, the pharmaceutical company reported Tuesday, as new approvals helped ...

In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI ®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of ...

One of the primary reasons is the impressive performance of Carvykti, which has demonstrated strong sales growth in the third quarter. This growth is attributed to increased manufacturing capacity ...

Legend Biotech Corp (NASDAQ:LEGN), a biopharmaceutical company specializing in novel cell therapies for oncology, has been making waves in the healthcare sector with its flagship product, Carvykti. As ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...